INSUQUICK is 100% Made in India with the potential to improve treatment access for people with diabetes
Chennai: USV Pvt Ltd and Biogenomics announced the launch of INSUQUICK®, India’s first biosimilar Insulin Aspart, which will improve access for people with diabetes.
Diabetes is a growing healthcare concern in India as nearly 11.4% of the country’s adult population, which accounts for 101 million people, are living with diabetes. Besides this, there are an additional 136 million people who are pre-diabetic and who have a high propensity to convert into diabetes in a short time.
InsuQuick is a “Make in India” product, developed and manufactured using 100% indigenous technology, and has undergone a robust clinical program to ensure global quality standards. It is available in all metros, and Tier I/II cities.
Mr Prashant Tewari, Managing Director, USV Pvt LTD, said,” We are committed to improving the quality of lives of people with diabetes. Strengthening our resolve, As a leader in the oral anti-diabetes segment, our entry into injectables is a strategic step towards bolstering our market presence and our aspiration to lead in the diabetes market. We have collaborated with Biogenomics to provide global-quality insulin aspart for our people with diabetes.
